Glenmark Pharmaceuticals has redeemed U.S. $182,500,000 in aggregate
principal amount of its 2021 Notes, representing approximately 91.25% of the aggregate principal amount of the 2021 Notes at the time of initial listing. As on the date of this announcement, U.S. $ 17,500,000 in aggregate principal amount of the 2021 Notes remain outstanding.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
